Sexual dysfunction in patients with chronic prostatitis and its treatment


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim: to study the frequency and type of sexual disorders in patients with chronic prostatitis (CP) and to evaluate the efficiency of Vitaprost and the biologically active complex NeuroDose in treating sexual dysfunctions. Materials and methods. The study was conducted in 2015-2019 and consisted of two stages. Study design: At the first stage, the frequency and type of sexual disorders were evaluated in 422 patients with CP. Standard methods for examining patients with CP included Loran-Segal questionnaire of male copulative function (MCF), International Index of Erectile Function (IIEF-5), ICEF-5, criteria of premature ejaculation, Treatment Satisfaction Visual Analogue Scale of orgasm quality and Hospital Anxiety and Depression Scale (HADS). Patients received standard 6-week complex therapy for CP. After that, at the second stage, 244 patients with sexual dysfunction (premature ejaculation, decreased intensity of orgasm) received Vitaprost and the NeuroDose biocomplex for 2 months. Results. Sexual disorders were detected in 77% of patients with CP. The main disorders were premature ejaculation (60.9%) and decreased intensity of orgasm (43.8%), which often occurred simultaneously. Two-month therapy of sexual dysfunction with Vitaprost and NeuroDose was effective in 94.3% of patients. Good results were observed in 80.3% of cases, while satisfactory results were obtained in 14% of patients. According to MCF, total copulative function increased by 46%, the duration of sexual intercourse increased from 1.1+0.4 min to 4.1+0.4 min (p<0.001) with an absence of premature ejaculation in 81.6% of patients, the intensity of orgasm increased from 3.8+0.4 to 8.0+0.5 (p<0.001) points, and the number of patients with neuropsychiatric symptoms associated mainly with sexual dysfunction decreased by 69.3%. Conclusion. Premature ejaculation and decreased intensity of orgasm are the most common sexual disorders in CP, and the combination of Vitaprost and dietary supplements NeuroDose is highly effective for their treatment.

Full Text

Restricted Access

About the authors

M. I Davidov

FGBOU VO “Academician Ye. A. Vagner Perm State Medical University” of the Ministry of Healthcare of the Russian Federation

Email: midavidov@mail.ru

References

  1. Интегративная урология. Руководство для врачей. Под ред. П.В. Глыбочко, Ю.Г. Аляева. М: Медфорум. 2014:314-374
  2. Rees J., Abrahams M., Doble A., Cooper A. Prostatitis Expert Reference Group (PERG) Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int.2015;116(4):509-525. doi: 10.1111/bju.13101.
  3. Holt J.D., Garrett W.A., McCurry T.K., Teichman J.M. Common question about chronic prostatitis: a systematic review. Am Fam Physician. 2016;93(4):29-33.
  4. Liang C.Z., Zhang X.J., Hao Z.Y., Shi H.Q., Wang K.X. Prevalence of sexual dysfunction in Chinese men with chronic prostatitis. BJU Int. 2004;93:568-570.
  5. Laumann E.O., Nicolosi A., Glasser D.B., Paik A., Gingell C., Moreira E. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res. 2005;17:39-57.
  6. Ахвледиани Н.Д., Аляев Ю.Г., Винаров А.З. Роль хронического простатита в каузальном генезе преждевременного семяизвержения. Андрология и генитальная хирургия. 2011; 1:21-26
  7. Ахвледиани Н.Д. Преждевременное семяизвержение: оценка современного состояния проблемы. Урология. 2018; 4 (Прил.1): 46-51. Doi:https://dx.doi.org/10.18565/urology.2018.4(Suppl.1): 46-51.
  8. Камалов А.А., Ходырева Л.А., Дудырева А.А., Карпов В.К., Охоботов Д. А., Старосельская М. А., Давидов М. И., Кузьмин М. Д. Результаты мультицентрового неинтервенционного исследования эффективности и безопасности применения комплекса НейроДоз при сексуальных дисфункциях у мужчин. Урология. 2016; 1(Прил. 1): 47-53
  9. Тер-Аванесов Г.В. Эффективность препарата НейроДоз у мужчин с преждевременной эякуляцией. Клиническое пособие для врачей. Пенткрофт фарма. 2012:2-11
  10. Виноградов И.В., Коршунов М.Н., Коршунова Е.С. Возможности применения биокомплекса НейроДоз для лечения больных вторичной преждевременной эякуляцией на фоне хронического простатита. Андрология и генитальная хирургия. 2015;6:56-60
  11. Пушкарь Д.Ю., Колонтарев К.Б. Оптимизация терапии больных эректильной дисфункцией. Урология. 2015;4:90-95
  12. Ахвледиани Н.Д., Матюхов И.П. Новые данные об эффективности лечения эректильной дисфункции, ассоциированной с вторичным преждевременным семяизвержением, с применением тадалафила и его комбинации с НейроДозом. Урология. 2016;5:1-4
  13. Урология. Российские клинические рекомендации/Под ред. Ю.Г. Аляева, П.В. Глыбочко, Д.Ю. Пушкаря. М.: ГЭОТАР-Медиа; 2018. 480 с
  14. Ткачук В.Н. Хронический простатит. М.: Медицина.; 2006: 240
  15. Лоран О.Б., Сегал А.С. Система суммарной оценки симптомов при хроническом простатите (СОС - ХП). Урология. 2001;5:16-19
  16. Hatzimouratidis K., Giuliano F., Moncada I., Muneer A., Salonia A., Verze P., Parnham A., Serefoglu E.C. EAU Guidelines on Erectile Dysfunction, Premature Ejaculation, Penile Curvature and Priapism; 2018: 258
  17. Donatucci C.F. Etiology of ejaculation and pathophysiology of premature ejaculation. J Sex Med. 2006;3(4):303- 308

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies